Skip to content
Giannis Mountzios· @g_mountzios · X·· 14 hours agoScore70

DELLPHI-305

Body · original

#ESMO26 Presidential 1
Excellent state-of-the art discussion on #Dellphi-305 by the 1@only @StephenVLiu
emphasizing on:

➡️ 1L maintenance Tarla setting a new SoC with a mOS of>20 months
❓High attrition rate from induction to maintenance, need for earlier TCE ( Dellphi-312)
❌Only 19% of pts in control arm received 2L Tarla post-progression reflecting access hurdles
✅ Global access to Tarla will make innovation meaningful for our patients
@@myESMO #ESMOAmbassadors

235 views · 7 likes · 2 reposts · 0 replies

Conference abstracts
LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

Source: Giannis Mountzios · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org